Researchers determined that patients with Wolfram syndrome have impaired smell identification abilities and blunted perceptions of certain taste stimuli, according to a study published in the Orphanet Journal of Rare Diseases.
Researchers determined patients with Wolfram syndrome have impaired smell identification abilities and blunted perceptions of certain taste stimuli, according to a study published in the Orphanet Journal of Rare Diseases.
Wolfram syndrome is a genetic disease in which patients exhibit insulin-dependent diabetes, optic nerve atrophy, sensorineural hearing loss, and neurodegeneration. Approximately 1 in 770,000 people have Wolfram syndrome worldwide. Although a common clinical marker of neurodegenerative diseases is olfactory disfunction, currently there are only limited data from standardized tests measuring the symptom in Wolfram syndrome.
To test whether the neurodegenerative disease affected olfactory dysfunction, researchers had 40 patients and 2 sex- and age-matched control groups complete the University of Pennsylvania Smell Identification Test (UPSIT). One control group was comprised of individuals with type 1 diabetes (T1D) and the other control group was healthy.
In order to assess taste function in participants, researchers used the National Institutes of Health Toolbox. This test is used to assess sucrose (sweet) taste preference and measure perceived intensity of sucrose, sodium chloride (salty), and quinine hydrochloride (bitter) tastes both on the tip of the tongue (regional test) and the patient’s whole mouth.
Overall, patients with Wolfram syndrome scored significantly lower on UPSIT than those with T1D and healthy controls (P <.001). This led researchers to conclude that patients with Wolfram syndrome had impaired abilities to identify smells. Smell sensitivity was not significantly different among all 3 groups.
In addition, “patients with Wolfram syndrome had a blunted perception of sweetness and saltiness when taste stimuli were applied regionally (P <.05),” researchers said. They continued, “differences in perceived intensity were no longer significant among groups when taste stimuli were tasted with the whole mouth.”
Researchers hope that by identifying the impact of the disease on taste and smell, these biomarkers could be used to evaluate the progression of the disease and measure effectiveness of potential treatments.
“Wolfram syndrome was associated with qualitative olfactory dysfunction that was not secondary to olfactory sensitivity or diabetes,” researchers concluded. In the future, longitudinal studies on taste and smell perception should be conducted in patients with Wolfram syndrome, so as to potentially use chemical senses as clinical markers to determine disease progression.
Reference
Alfaro R, Doty T, Narayanan A, et al. Taste and smell function in Wolfram syndrome. Orphanet J Rare Dis. 2020;15(57). doi: 10.1186/s13023-020-1335-7.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
November 21st 2023Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Odevixibat Safe for Alagille Syndrome Based on Hepatic Changes
November 8th 2023Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen